PCN87 Budget Impact Analysis (BIA) of Ruxolitinib for Treatment of Intermediate-2 or High Risk IPSS Myelofibrosis in the Brazilian Public Healthcare System (SUS)
Abstract
Authors
A. Nonino H. Kim A.P.A.D.S. Flora
A. Nonino H. Kim A.P.A.D.S. Flora
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now